<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02526225</url>
  </required_header>
  <id_info>
    <org_study_id>1412-Z-YXET-ZS-RE</org_study_id>
    <nct_id>NCT02526225</nct_id>
  </id_info>
  <brief_title>A Safety and Effective Study of Ginkgolides Diterpene Lactone Meglumine Injection in the Treatment of Ischemic Stroke.</brief_title>
  <official_title>A Randomized,Double Blind,Placebo Parallel Controlled,Multicenter Clinical Sthdy of Ginkgo Diterpene Lactone Meglumine Injection for Acute Ischemic Stroke Efficacy Safety.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Science and Technology of the People´s Republic of China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Bionovo Medicine Development Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ministry of Science and Technology of the People´s Republic of China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety and effectivity of Ginkgo diterpene lactone
      meglumine injection tn the treatment of acute ischemic stroke
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After randomized to 90 + 7 days mRS 0-1 points is the Primary Outcome Measure,evaluate the
      safety and effectivity of Ginkgo diterpene lactone meglumine injection tn the treatment of
      acute ischemic stroke
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with Modified Rankin Scale (mRS) less than or equal to 1 .</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with National Institutes of Health Stroke Score (NIHSS) rising 4 or more points, three points, two points, one of the subjects changes from baseline to randomized 7 days.</measure>
    <time_frame>Baseline, 7days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with National Institutes of Health Stroke Score (NIHSS) reducing 4 points or more changes from baseline to randomized 7 days,14 days.</measure>
    <time_frame>Baseline,7 days,14 days,</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with Modified Rankin Scale (mRS) reaching 0-2 .</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Montreal Cognitive Assessment (MoCA) scale changes from baseline to randomized 14 days,90 days.</measure>
    <time_frame>Baseline,14 days,90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The EuroQol-5 Dimensions (EQ-5D) scale changes from baseline to randomized 14 days,90 days.</measure>
    <time_frame>Baseline,14 days,90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The all-cause mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke recurrence rate</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite incidence of vascular events</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3452</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>ginkgo diterpene lactone meglumine injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ginkgo diterpene lactone meglumine injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ginkgo diterpene lactone meglumine injection simulation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ginkgo diterpene lactone meglumine injection simulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ginkgo diterpene lactone meglumine injection</intervention_name>
    <description>5 ml,oral,5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.</description>
    <arm_group_label>ginkgo diterpene lactone meglumine injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ginkgo diterpene lactone meglumine injection simulation</intervention_name>
    <description>5 ml,oral,5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.</description>
    <arm_group_label>Ginkgo diterpene lactone meglumine injection simulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18 to 80 years of age, and gender not limited。

          2. Within 48 hours of stroke onset of ischemic stroke (diagnosis standard by the Chinese
             medical association of the fourth national conference on cerebrovascular disease);

          3. The first onset, or always not obvious legacy of stroke sequela (mRS acuities were
             before the onset of 1);

          4. The degree of nerve function defect score (NIHSS) score 4 to 24 points, body movement
             component (NIHSS score paragraphs 5 and 6) total score 2 points or higher;

          5. Understand and voluntarily signed informed consent.

        Exclusion Criteria:

          1. Head imaging studies have confirmed that, encephalitis, brain tumor, brain abscess and
             cause similar symptoms of disease, or confirm with hemorrhagic cerebral infarction,
             epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid
             hemorrhage, etc.

          2. The serious disturbance of consciousness (Ia NIHSS score 2 points or higher);

          3. With hemorrhagic disease or have a bleeding tendency, or have a lower limb venous
             thrombosis;

          4. Serious abnormal liver and kidney function, liver function laboratory indexes of ALT &gt;
             3 ULN, renal laboratory ULN Cr &gt; 1.5);

          5. A history of mental illness or dementia patients;

          6. Severe organ or other systemic disease, accompanied by any organ or system of
             malignant tumor, or ongoing anti-tumor treatment, the estimated lifetime &lt; 3 months;

          7. Significant drug or alcohol abuse;

          8. Allergic constitution, as well as to two or more drugs or food allergies;This medicine
             ingredients allergy or known;

          9. Have pregnancy (check blood HCG positive screening tests, namely HCG &gt; 5 miu/mL),
             during the test preparation is pregnancy or lactation in women;

         10. In the past three months in other clinical trials;

         11. Researchers do not determine poor adherence, or any other suitable for patients to
             participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yongjun wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital,Capital Medical University,Bgeijing,China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>August 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2015</study_first_posted>
  <last_update_submitted>February 25, 2016</last_update_submitted>
  <last_update_submitted_qc>February 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Science and Technology of the People´s Republic of China</investigator_affiliation>
    <investigator_full_name>yongjun wang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>acute ischemic stroke</keyword>
  <keyword>safety and effectiveness</keyword>
  <keyword>Ginkgo diterpene lactone meglumine injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

